Reframing Kidney Health in the Era of SGLT2 Innovation
KEITH BELLOVICH D.O., MBA, CHIEF NEPHROLOGIST, STRIVE HEALTHSGLT2 inhibitors represent a seismic shift in how we treat chronic kidney disease. Once reserved for blood sugar management in patients with diabetes, these medications now offer kidney

protection independent of their glycemic effects — reducing the risk of disease progression by 30 to 40 percent and lowering cardiovascular events. Yet despite robust clinical evidence, only about 20 percent of eligible kidney disease patients receive SGLT2 therapy, compared with nearly 70 percent adoption of legacy ACE inhibitors. The gap between promise and practice reflects not a scientific shortfall, but a systems problem.
In this piece, Strive’s Chief Nephrologist Keith Bellovich, D.O., MBA, explores how SGLT2 inhibitors work at the cellular level, which systemic barriers delay their adoption and how value-based care partnerships create the infrastructure to translate clinical evidence into real-world outcomes for the millions of insured Americans living with kidney disease.
Download the full piece by filling out the form below.
This form requires cookies to function. Please update your cookie preferences to view this form.


